N-Power Medicine, a Redwood City, CA-based company improving clinical trial processes, acquired Syapse Holdings, a company which specializes in precision medicine solutions for community cancer centers.
The amount of the deal was not disclosed. N-Power’s acquisition of Syapse was completed as a stock-for-stock exchange on Dec. 30, 2024. Innovatus Capital Partners LLC, Syapse’s lead institutional investor, joins N-Power’s existing investors, including the Merck Global Health Innovation Fund (GHI) and a U.S. based healthcare-focused investor, in providing ongoing funding for N-Power’s vision.
This transaction will accelerate the scale-up of N-Power’s prospective clinical research model, adding an extensive network of community health systems and 1,000+ community oncologists across the U.S.
Led by CEO Michael Mentesana, Syapse is dedicated to extinguishing the fear and burden of oncology and other serious diseases by advancing real-world care and transforming data into evidence in collaboration with its network of partners, who are committed to improving patients’ lives through community health systems.
Founded in 2021, and led by CEO Mark Lee, N-Power Medicine is a clinical research and drug development platform company that aims to boost clinical trial participation to accelerate oncology drug development.
FinSMEs
11/01/2025